Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 29 | 2024 | 1897 | 3.140 |
Why?
|
| Botswana | 29 | 2023 | 75 | 1.820 |
Why?
|
| Malaria Vaccines | 1 | 2022 | 17 | 0.810 |
Why?
|
| Malaria | 1 | 2022 | 87 | 0.770 |
Why?
|
| HIV Seropositivity | 1 | 2022 | 121 | 0.750 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2020 | 11 | 0.700 |
Why?
|
| Genomics | 5 | 2023 | 1502 | 0.470 |
Why?
|
| Anti-HIV Agents | 3 | 2024 | 319 | 0.450 |
Why?
|
| Food Supply | 1 | 2014 | 101 | 0.430 |
Why?
|
| Pharmacogenetics | 2 | 2023 | 184 | 0.390 |
Why?
|
| Adolescent | 22 | 2023 | 19349 | 0.320 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2023 | 217 | 0.320 |
Why?
|
| Child | 20 | 2023 | 24384 | 0.310 |
Why?
|
| Humans | 44 | 2024 | 125085 | 0.300 |
Why?
|
| Mental Disorders | 2 | 2023 | 826 | 0.240 |
Why?
|
| Africa South of the Sahara | 5 | 2023 | 114 | 0.240 |
Why?
|
| HLA-C Antigens | 1 | 2024 | 6 | 0.230 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2024 | 8 | 0.230 |
Why?
|
| Disclosure | 2 | 2023 | 151 | 0.230 |
Why?
|
| Benzoxazines | 1 | 2024 | 24 | 0.230 |
Why?
|
| Alkynes | 1 | 2024 | 26 | 0.230 |
Why?
|
| Cyclopropanes | 1 | 2024 | 68 | 0.220 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2024 | 125 | 0.220 |
Why?
|
| Feedback | 5 | 2022 | 164 | 0.220 |
Why?
|
| Wolves | 1 | 2023 | 4 | 0.210 |
Why?
|
| Thinness | 1 | 2023 | 70 | 0.210 |
Why?
|
| Counselors | 1 | 2023 | 22 | 0.210 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2022 | 231 | 0.200 |
Why?
|
| Dog Diseases | 1 | 2023 | 50 | 0.200 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2022 | 31 | 0.200 |
Why?
|
| Nicotine | 1 | 2023 | 142 | 0.200 |
Why?
|
| Thrombocytosis | 1 | 2022 | 34 | 0.200 |
Why?
|
| Self-Injurious Behavior | 1 | 2023 | 63 | 0.200 |
Why?
|
| International Educational Exchange | 1 | 2022 | 17 | 0.200 |
Why?
|
| Patient Compliance | 2 | 2016 | 474 | 0.190 |
Why?
|
| Social Stigma | 1 | 2022 | 69 | 0.190 |
Why?
|
| Anti-Retroviral Agents | 3 | 2023 | 140 | 0.190 |
Why?
|
| Immune Evasion | 1 | 2022 | 35 | 0.190 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2021 | 16 | 0.190 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 17 | 0.190 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2021 | 9 | 0.190 |
Why?
|
| Chloroquine | 1 | 2021 | 30 | 0.190 |
Why?
|
| Pregnancy | 6 | 2023 | 7193 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 235 | 0.180 |
Why?
|
| HIV-1 | 1 | 2024 | 464 | 0.180 |
Why?
|
| Suicide | 1 | 2023 | 175 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 226 | 0.170 |
Why?
|
| Oxazines | 1 | 2020 | 25 | 0.170 |
Why?
|
| Dyslipidemias | 1 | 2023 | 234 | 0.170 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2020 | 39 | 0.170 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2022 | 240 | 0.170 |
Why?
|
| Adult | 9 | 2024 | 29628 | 0.170 |
Why?
|
| Brain Concussion | 1 | 2023 | 229 | 0.170 |
Why?
|
| Child, Orphaned | 1 | 2020 | 18 | 0.170 |
Why?
|
| Qualitative Research | 1 | 2023 | 539 | 0.170 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 450 | 0.170 |
Why?
|
| Motivation | 1 | 2022 | 319 | 0.160 |
Why?
|
| Malnutrition | 1 | 2022 | 205 | 0.160 |
Why?
|
| Pyridones | 1 | 2020 | 118 | 0.160 |
Why?
|
| Research Personnel | 1 | 2020 | 117 | 0.160 |
Why?
|
| Mothers | 1 | 2022 | 354 | 0.160 |
Why?
|
| Safe Sex | 1 | 2019 | 16 | 0.160 |
Why?
|
| Genome, Human | 2 | 2023 | 1274 | 0.150 |
Why?
|
| Piperazines | 1 | 2020 | 240 | 0.150 |
Why?
|
| Mental Health | 1 | 2021 | 346 | 0.150 |
Why?
|
| School Health Services | 1 | 2019 | 99 | 0.150 |
Why?
|
| Anemia | 1 | 2022 | 340 | 0.150 |
Why?
|
| Premature Birth | 1 | 2022 | 384 | 0.150 |
Why?
|
| Informed Consent | 1 | 2021 | 333 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 237 | 0.150 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 143 | 0.150 |
Why?
|
| Pregnancy Complications | 1 | 2022 | 513 | 0.140 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 454 | 0.140 |
Why?
|
| HIV | 3 | 2023 | 180 | 0.140 |
Why?
|
| Genetic Research | 3 | 2022 | 55 | 0.130 |
Why?
|
| Self Administration | 1 | 2016 | 43 | 0.130 |
Why?
|
| Young Adult | 4 | 2023 | 9052 | 0.130 |
Why?
|
| Female | 12 | 2024 | 66744 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2023 | 922 | 0.120 |
Why?
|
| Genetic Variation | 2 | 2021 | 1501 | 0.120 |
Why?
|
| Phylogeny | 3 | 2023 | 696 | 0.120 |
Why?
|
| Adolescent Behavior | 1 | 2016 | 169 | 0.120 |
Why?
|
| Tuberculosis | 1 | 2020 | 525 | 0.110 |
Why?
|
| Neuropsychological Tests | 3 | 2023 | 924 | 0.110 |
Why?
|
| Risk Factors | 6 | 2023 | 10285 | 0.110 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2013 | 2 | 0.100 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 17 | 0.100 |
Why?
|
| HIV Protease Inhibitors | 1 | 2013 | 54 | 0.100 |
Why?
|
| Lamivudine | 2 | 2022 | 25 | 0.100 |
Why?
|
| Ritonavir | 1 | 2013 | 54 | 0.100 |
Why?
|
| Uganda | 2 | 2023 | 79 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2512 | 0.100 |
Why?
|
| South Africa | 2 | 2022 | 99 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2023 | 724 | 0.090 |
Why?
|
| Growth Disorders | 2 | 2023 | 209 | 0.090 |
Why?
|
| Mass Screening | 3 | 2021 | 785 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2013 | 270 | 0.090 |
Why?
|
| Tanzania | 2 | 2021 | 69 | 0.090 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 188 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2023 | 16326 | 0.080 |
Why?
|
| Alleles | 2 | 2023 | 1616 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2021 | 340 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2022 | 4814 | 0.070 |
Why?
|
| Genotype | 2 | 2023 | 2562 | 0.070 |
Why?
|
| Infant | 1 | 2022 | 12475 | 0.070 |
Why?
|
| Medication Adherence | 2 | 2021 | 399 | 0.060 |
Why?
|
| Male | 7 | 2023 | 61465 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3298 | 0.060 |
Why?
|
| HIV Antigens | 1 | 2024 | 12 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 2890 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2A6 | 1 | 2023 | 13 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2023 | 14 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2022 | 14004 | 0.050 |
Why?
|
| Problem Solving | 1 | 2023 | 63 | 0.050 |
Why?
|
| Prognosis | 2 | 2022 | 4637 | 0.050 |
Why?
|
| Nevirapine | 1 | 2022 | 15 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2023 | 126 | 0.050 |
Why?
|
| Platelet Count | 1 | 2022 | 136 | 0.050 |
Why?
|
| Stillbirth | 1 | 2022 | 79 | 0.050 |
Why?
|
| Maternal Mortality | 1 | 2022 | 79 | 0.050 |
Why?
|
| Dogs | 1 | 2023 | 774 | 0.050 |
Why?
|
| Cholesterol, HDL | 1 | 2023 | 357 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2024 | 504 | 0.050 |
Why?
|
| Counseling | 1 | 2023 | 218 | 0.050 |
Why?
|
| Ecosystem | 1 | 2021 | 77 | 0.050 |
Why?
|
| Income | 1 | 2022 | 134 | 0.050 |
Why?
|
| Haplotypes | 1 | 2022 | 522 | 0.040 |
Why?
|
| Triglycerides | 1 | 2023 | 575 | 0.040 |
Why?
|
| Africa | 1 | 2021 | 133 | 0.040 |
Why?
|
| Executive Function | 1 | 2021 | 109 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2024 | 1506 | 0.040 |
Why?
|
| Cholesterol | 1 | 2023 | 540 | 0.040 |
Why?
|
| Protein Binding | 1 | 2024 | 1757 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 88 | 0.040 |
Why?
|
| Recombination, Genetic | 1 | 2022 | 448 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2024 | 2715 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 569 | 0.040 |
Why?
|
| Amino Acids | 1 | 2022 | 667 | 0.040 |
Why?
|
| Malawi | 1 | 2021 | 396 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 592 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1357 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2021 | 474 | 0.040 |
Why?
|
| Gene Pool | 1 | 2018 | 5 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2022 | 1080 | 0.040 |
Why?
|
| Geography | 1 | 2018 | 113 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 470 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 731 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 142 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 2062 | 0.040 |
Why?
|
| Global Health | 1 | 2022 | 563 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2018 | 188 | 0.030 |
Why?
|
| Curriculum | 1 | 2022 | 726 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2021 | 875 | 0.030 |
Why?
|
| Anxiety | 1 | 2023 | 959 | 0.030 |
Why?
|
| Aged | 2 | 2024 | 19859 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 729 | 0.030 |
Why?
|
| Psychology, Adolescent | 1 | 2014 | 32 | 0.030 |
Why?
|
| Psychology | 1 | 2014 | 58 | 0.030 |
Why?
|
| Depression | 1 | 2023 | 1236 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 385 | 0.030 |
Why?
|
| Attitude | 1 | 2014 | 116 | 0.030 |
Why?
|
| Raltegravir Potassium | 1 | 2013 | 2 | 0.030 |
Why?
|
| Darunavir | 1 | 2013 | 3 | 0.030 |
Why?
|
| Phenotype | 1 | 2022 | 4263 | 0.030 |
Why?
|
| Social Support | 1 | 2014 | 345 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 34219 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 267 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 6153 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 8205 | 0.020 |
Why?
|
| Mutation | 1 | 2022 | 5848 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5174 | 0.020 |
Why?
|
| Middle Aged | 1 | 2024 | 26919 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 12388 | 0.010 |
Why?
|